13 February 2024 : Original article
A Retrospective Study of Long-Term Outcomes in 16 ABO-Incompatible Deceased Donor Pediatric Liver Transplants from a National Transplant Center at Helsinki University Hospital, Finland, 1987-2022
Timo Jahnukainen
1ABCDEFG*, Inna Sareneva2CD, Jouni Lauronen 2DE, Elisa Ylinen 1DE, Juuso Tainio 1BCE, Arno Nordin 3BDE, Maria Hukkinen 4BE, Mikko P. Pakarinen 4AE, Hannu Jalanko 1ADE
DOI: 10.12659/AOT.941929
Ann Transplant 2024; 29:e941929
Table 3 Sensitization against HLA antigens and anti-ABO antibodies before and after liver transplantation among pediatric patients who have received an ABO-incompatible liver transplant in Finland.
| Patients with anti-HLA antibodies before LT, n (%)1 | 5 (30) |
| Median number of HLA mismatches, n (range)2 | |
| Class 1 | 1.5 (1–4) |
| Class 2 | 1.5 (0–2) |
| Positive leukocyte crossmatch before LT, n (%) | 1 (6) |
| Patients with anti-ABO antibodies before LT, n (%)3 | 9 (82) |
| Mean peak anti-ABO antibody titer before LT2 | |
| IgG ABO antibodies | 16 (0–32) |
| IgM ABO antibodies | 8 (0–32) |
| Patients with anti-ABO antibodies after LT, n (%)2 | 4 (36) |
| Mean peak anti-ABO antibody after LT2 | |
| IgG ABO antibodies | 21 (0–256) |
| IgM ABO antibodies | 19 (0–256) |
| 1 Data available from 15/16 patients; 2 available from 11/16 patients; 3 data available from 9/16 patients. LT – liver transplantation; HLA – human leukocyte antigen. | |